Inicio
Resultado de la búsqueda
9 búsqueda de la palabra clave 'Treatment'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigación
Psychogenic nonepileptic seizures in Latin America: A survey describing current practices / Lady Diana Ladino Malagón
Título : Psychogenic nonepileptic seizures in Latin America: A survey describing current practices Tipo de documento : documento electrónico Autores : Lady Diana Ladino Malagón, Autor asociado al HPTU Fecha de publicación : 2021 Títulos uniformes : Epilepsy & Behavior Idioma : Inglés (eng) Palabras clave : Diagnosis Barriers Health services Nonepileptic seizures Psychotherapy Treatment Resumen : Objective: Psychogenic nonepileptic seizures (PNES) are one of the most common differential diagnoses of epilepsy. This study provides an overview of diagnostic and treatment services for patients with PNES across Latin America. Methods: In 2017–2018, clinicians practicing in Latin America with responsibilities for patients with PNES were contacted to respond to a survey regarding the management of this disorder developed by the International League Against Epilepsy (ILAE) PNES Task Force. Results: Three hundred and sixty responses from 17 Latin American countries were analyzed. Most respondents were neurologists (81%) under 40 years of age (61%). Fifty-seven percent of professionals stated that they personally diagnose PNES, but only 33% stated that they provide follow-up, and only 20% that they recommend treatment. Many participants (54%) characterized themselves as either unfamiliar with the diagnosis or inexperienced in arranging treatment. Most respondents reported having access to brain magnetic resonance imaging (MRI; 88%) and routine electroencephalogram (EEG; 71%), 64% have the access to video-EEG longer than 8 h, and 54% of professionals performed video-EEG to confirm PNES diagnoses. Although cognitive–behavioral therapy was recognized as the treatment of choice (by 82% of respondents), there was little access to it (60%). In contrast, a high proportion of respondents reported using antidepressant (67%), antiseizure (57%), and antipsychotic medications (54%) as treatments for PNES. Significance: This study reveals several deficiencies in the diagnosis and treatment of patients with PNES in Latin America. The barriers are reinforced by lack of knowledge among the specialists and poor healthcare system support. There is inadequate access to prolonged video-EEG and psychotherapy. An inappropriate use of antiseizure medicines seems commonplace, and there are low follow-up rates by neurologists after the diagnosis. Multidisciplinary guidelines are required to improve the approach of patients with PNES. Mención de responsabilidad : Lady Diana Ladino, Vanessa Benjumea-Cuartas, Yamile Calle-López, Juan Pablo Orozco-Hernández, Diana Marcela Castrillón-Velilla, Reydmar López-González, Anilu Daza-Restrepo, Mario Alberto Genel Castillo, Markus Reuber, Alyssa Denton, José F Tellez-Zenteno Referencia : Epilepsy Behav. 2021 Jan;114(Pt A):107150. DOI (Digital Object Identifier) : 10.1016/j.yebeh.2020.107150 PMID : 32507294 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1525505020303292 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Psychogenic nonepileptic seizures in Latin America: A survey describing current practices [documento electrónico] / Lady Diana Ladino Malagón, Autor asociado al HPTU . - 2021.
Obra : Epilepsy & Behavior
Idioma : Inglés (eng)
Palabras clave : Diagnosis Barriers Health services Nonepileptic seizures Psychotherapy Treatment Resumen : Objective: Psychogenic nonepileptic seizures (PNES) are one of the most common differential diagnoses of epilepsy. This study provides an overview of diagnostic and treatment services for patients with PNES across Latin America. Methods: In 2017–2018, clinicians practicing in Latin America with responsibilities for patients with PNES were contacted to respond to a survey regarding the management of this disorder developed by the International League Against Epilepsy (ILAE) PNES Task Force. Results: Three hundred and sixty responses from 17 Latin American countries were analyzed. Most respondents were neurologists (81%) under 40 years of age (61%). Fifty-seven percent of professionals stated that they personally diagnose PNES, but only 33% stated that they provide follow-up, and only 20% that they recommend treatment. Many participants (54%) characterized themselves as either unfamiliar with the diagnosis or inexperienced in arranging treatment. Most respondents reported having access to brain magnetic resonance imaging (MRI; 88%) and routine electroencephalogram (EEG; 71%), 64% have the access to video-EEG longer than 8 h, and 54% of professionals performed video-EEG to confirm PNES diagnoses. Although cognitive–behavioral therapy was recognized as the treatment of choice (by 82% of respondents), there was little access to it (60%). In contrast, a high proportion of respondents reported using antidepressant (67%), antiseizure (57%), and antipsychotic medications (54%) as treatments for PNES. Significance: This study reveals several deficiencies in the diagnosis and treatment of patients with PNES in Latin America. The barriers are reinforced by lack of knowledge among the specialists and poor healthcare system support. There is inadequate access to prolonged video-EEG and psychotherapy. An inappropriate use of antiseizure medicines seems commonplace, and there are low follow-up rates by neurologists after the diagnosis. Multidisciplinary guidelines are required to improve the approach of patients with PNES. Mención de responsabilidad : Lady Diana Ladino, Vanessa Benjumea-Cuartas, Yamile Calle-López, Juan Pablo Orozco-Hernández, Diana Marcela Castrillón-Velilla, Reydmar López-González, Anilu Daza-Restrepo, Mario Alberto Genel Castillo, Markus Reuber, Alyssa Denton, José F Tellez-Zenteno Referencia : Epilepsy Behav. 2021 Jan;114(Pt A):107150. DOI (Digital Object Identifier) : 10.1016/j.yebeh.2020.107150 PMID : 32507294 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1525505020303292 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares (1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001374 AC-2020-052 Archivo digital Producción Científica Artículos científicos Disponible Recurrence of hepatocellular carcinoma after liver transplantation: Prognostic and predictive factors of survival in a Latin American cohort / Sergio Iván Hoyos Duque
Título : Recurrence of hepatocellular carcinoma after liver transplantation: Prognostic and predictive factors of survival in a Latin American cohort Tipo de documento : documento electrónico Autores : Sergio Iván Hoyos Duque, Autor asociado al HPTU Fecha de publicación : 2021 Títulos uniformes : Liver International Idioma : Inglés (eng) Palabras clave : hepatocellular carcinoma liver transplantation prognosis recurrence treatment Resumen : Background & aim: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) has a poor prognosis, and the adjusted effect of different treatments on post-recurrence survival (PRS) has not been well defined. This study aims to evaluate prognostic and predictive variables associated with PRS. Methods: This Latin American multicenter retrospective cohort study included HCC patients who underwent LT between the years 2005-2018. We evaluated the effect of baseline characteristics at time of HCC recurrence diagnosis and PRS (Cox regression analysis). Early recurrences were those occurring within 12 months of LT. To evaluate the adjusted treatment effect for HCC recurrence, a propensity score matching analysis was performed to assess the probability of having received any specific treatment for recurrence. Results: From a total of 1085 transplanted HCC patients, the cumulative incidence of recurrence was 16.6% (CI 13.5-20.3), with median time to recurrence of 13.0 months (IQR 6.0-26.0). Factors independently associated with PRS were early recurrence (47.6%), treatment with sorafenib and surgery/trans-arterial chemoembolization (TACE). Patients who underwent any treatment presented "early recurrences" less frequently, and more extrahepatic metastasis. This unbalanced distribution was included in the propensity score matching, with correct calibration and discrimination (receiving operator curve of 0.81 [CI 0.72;0.88]). After matching, the adjusted effect on PRS for any treatment was HR of 0.2 (0.10;0.33); P < .0001, for sorafenib therapy HR of 0.4 (0.27;0.77); P = .003, and for surgery/TACE HR of 0.4 (0.18;0.78); P = .009. Conclusion: Although early recurrence was associated with worse outcome, even in this population, systemic or locoregional treatments were associated with better PRS. Mención de responsabilidad : Claudia Maccali, Aline L Chagas, Ilka Boin, Emilio Quiñonez, Sebastián Marciano, Mario Vilatobá, Adriana Varón, Margarita Anders, Sergio Hoyos Duque, Agnaldo S Lima, Josemaría Menendez, Martín Padilla-Machaca, Jaime Poniachik, Rodrigo Zapata, Martín Maraschio, Ricardo Chong Menéndez, Linda Muñoz, Diego Arufe, Rodrigo Figueroa, Alejandro Soza, Martín Fauda, Simone R Perales, Rodrigo Vergara Sandoval, Carla Bermudez, Oscar Beltran, Isabel Arenas Hoyos, Lucas McCormack, Francisco Juan Mattera, Adrián Gadano, Jose H Parente García , Claudia Megumi Tani, Luiz Augusto Carneiro D'Albuquerque, Flair J Carrilho, Marcelo Silva, Federico Piñero Referencia : Liver Int. 2021 Apr;41(4):851-862. DOI (Digital Object Identifier) : 10.1111/liv.14736 PMID : 33217193 En línea : https://onlinelibrary.wiley.com/doi/10.1111/liv.14736 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Recurrence of hepatocellular carcinoma after liver transplantation: Prognostic and predictive factors of survival in a Latin American cohort [documento electrónico] / Sergio Iván Hoyos Duque, Autor asociado al HPTU . - 2021.
Obra : Liver International
Idioma : Inglés (eng)
Palabras clave : hepatocellular carcinoma liver transplantation prognosis recurrence treatment Resumen : Background & aim: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) has a poor prognosis, and the adjusted effect of different treatments on post-recurrence survival (PRS) has not been well defined. This study aims to evaluate prognostic and predictive variables associated with PRS. Methods: This Latin American multicenter retrospective cohort study included HCC patients who underwent LT between the years 2005-2018. We evaluated the effect of baseline characteristics at time of HCC recurrence diagnosis and PRS (Cox regression analysis). Early recurrences were those occurring within 12 months of LT. To evaluate the adjusted treatment effect for HCC recurrence, a propensity score matching analysis was performed to assess the probability of having received any specific treatment for recurrence. Results: From a total of 1085 transplanted HCC patients, the cumulative incidence of recurrence was 16.6% (CI 13.5-20.3), with median time to recurrence of 13.0 months (IQR 6.0-26.0). Factors independently associated with PRS were early recurrence (47.6%), treatment with sorafenib and surgery/trans-arterial chemoembolization (TACE). Patients who underwent any treatment presented "early recurrences" less frequently, and more extrahepatic metastasis. This unbalanced distribution was included in the propensity score matching, with correct calibration and discrimination (receiving operator curve of 0.81 [CI 0.72;0.88]). After matching, the adjusted effect on PRS for any treatment was HR of 0.2 (0.10;0.33); P < .0001, for sorafenib therapy HR of 0.4 (0.27;0.77); P = .003, and for surgery/TACE HR of 0.4 (0.18;0.78); P = .009. Conclusion: Although early recurrence was associated with worse outcome, even in this population, systemic or locoregional treatments were associated with better PRS. Mención de responsabilidad : Claudia Maccali, Aline L Chagas, Ilka Boin, Emilio Quiñonez, Sebastián Marciano, Mario Vilatobá, Adriana Varón, Margarita Anders, Sergio Hoyos Duque, Agnaldo S Lima, Josemaría Menendez, Martín Padilla-Machaca, Jaime Poniachik, Rodrigo Zapata, Martín Maraschio, Ricardo Chong Menéndez, Linda Muñoz, Diego Arufe, Rodrigo Figueroa, Alejandro Soza, Martín Fauda, Simone R Perales, Rodrigo Vergara Sandoval, Carla Bermudez, Oscar Beltran, Isabel Arenas Hoyos, Lucas McCormack, Francisco Juan Mattera, Adrián Gadano, Jose H Parente García , Claudia Megumi Tani, Luiz Augusto Carneiro D'Albuquerque, Flair J Carrilho, Marcelo Silva, Federico Piñero Referencia : Liver Int. 2021 Apr;41(4):851-862. DOI (Digital Object Identifier) : 10.1111/liv.14736 PMID : 33217193 En línea : https://onlinelibrary.wiley.com/doi/10.1111/liv.14736 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares (1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001640 AC-2020-134 Archivo digital Producción Científica Artículos científicos Disponible The use of cannabis as a treatment for epilepsy in adult patients: are side effects a limitation of use? / Lady Diana Ladino Malagón
Título : The use of cannabis as a treatment for epilepsy in adult patients: are side effects a limitation of use? Tipo de documento : documento electrónico Autores : Lady Diana Ladino Malagón, Autor asociado al HPTU Fecha de publicación : 2020 Títulos uniformes : Journal of Clinical Neurophysiology Idioma : Inglés (eng) Palabras clave : Cannabis CBD Epilepsy Treatment Adults Resumen : Marijuana is the dried leaves, stems, and flowers of a 1- to 5-m weed originating from Central Asia. The most common varieties are Cannabis sativa and Cannabis indica. It is usually inhaled as smoke but can also be used as a vapor, taken by mouth as a spray, ingested in tea or as butter in baked goods, or in capsule form and used as an oil. Cannabis has been widely used to treat many medical conditions such as multiple sclerosis symptoms, mood disorders, pain, sleep disorders, and seizures among others. Preclinical and clinical studies have been done over the past decade, among them there are few randomized placebo-controlled trials. In the last few years, Cannabis has been proposed as a potential therapy for patients with drug-resistant epilepsy. This review analyzes the best information about the use of cannabis in adult patients, reviewing aspects of efficacy and safety. Mención de responsabilidad : Jose F Téllez-Zenteno, Lady D Ladino, Lizbeth Hernández-Ronquillo Referencia : J Clin Neurophysiol. 2020;37(1):9–14. DOI (Digital Object Identifier) : 10.1097/WNP.0000000000000637 PMID : 31895185 En línea : https://journals.lww.com/clinicalneurophys/Abstract/2020/01000/The_Use_of_Cannab [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis The use of cannabis as a treatment for epilepsy in adult patients: are side effects a limitation of use? [documento electrónico] / Lady Diana Ladino Malagón, Autor asociado al HPTU . - 2020.
Obra : Journal of Clinical Neurophysiology
Idioma : Inglés (eng)
Palabras clave : Cannabis CBD Epilepsy Treatment Adults Resumen : Marijuana is the dried leaves, stems, and flowers of a 1- to 5-m weed originating from Central Asia. The most common varieties are Cannabis sativa and Cannabis indica. It is usually inhaled as smoke but can also be used as a vapor, taken by mouth as a spray, ingested in tea or as butter in baked goods, or in capsule form and used as an oil. Cannabis has been widely used to treat many medical conditions such as multiple sclerosis symptoms, mood disorders, pain, sleep disorders, and seizures among others. Preclinical and clinical studies have been done over the past decade, among them there are few randomized placebo-controlled trials. In the last few years, Cannabis has been proposed as a potential therapy for patients with drug-resistant epilepsy. This review analyzes the best information about the use of cannabis in adult patients, reviewing aspects of efficacy and safety. Mención de responsabilidad : Jose F Téllez-Zenteno, Lady D Ladino, Lizbeth Hernández-Ronquillo Referencia : J Clin Neurophysiol. 2020;37(1):9–14. DOI (Digital Object Identifier) : 10.1097/WNP.0000000000000637 PMID : 31895185 En línea : https://journals.lww.com/clinicalneurophys/Abstract/2020/01000/The_Use_of_Cannab [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares (1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001305 AC-2020-009 Archivo digital Producción Científica Artículos científicos Disponible First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR) / Ruth María Eraso Garnica
Título : First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR) Tipo de documento : documento electrónico Autores : Ruth María Eraso Garnica, Autor asociado al HPTU Fecha de publicación : 2018 Títulos uniformes : Annals of the Rheumatic Diseases Idioma : Inglés (eng) Palabras clave : Lupus nephritis systemic lupus erythematosus treatment Resumen : Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therapeutic guidelines are developed. The objective of the study is to develop clinical practice guidelines for Latin American patients with lupus. Two independent teams (rheumatologists with experience in lupus management and methodologists) had an initial meeting in Panama City, Panama, in April 2016. They selected a list of questions for the clinical problems most commonly seen in Latin American patients with SLE. These were addressed with the best available evidence and summarised in a standardised format following the Grading of Recommendations Assessment, Development and Evaluation approach. All preliminary findings were discussed in a second face-to-face meeting in Washington, DC, in November 2016. As a result, nine organ/system sections are presented with the main findings; an 'overarching' treatment approach was added. Special emphasis was made on regional implementation issues. Best pharmacologic options were examined for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, haematological manifestations and the antiphospholipid syndrome. The roles of main therapeutic options (ie, glucocorticoids, antimalarials, immunosuppressant agents, therapeutic plasma exchange, belimumab, rituximab, abatacept, low-dose aspirin and anticoagulants) were summarised in each section. In all cases, benefits and harms, certainty of the evidence, values and preferences, feasibility, acceptability and equity issues were considered to produce a recommendation with special focus on ethnic and socioeconomic aspects. Guidelines for Latin American patients with lupus have been developed and could be used in similar settings. Mención de responsabilidad : Bernardo A Pons-Estel, Eloisa Bonfa, Enrique R Soriano, Mario H Cardiel, Ariel Izcovich, Federico Popoff, Juan M Criniti, Gloria Vásquez, Loreto Massardo, Margarita Duarte, Leonor A Barile-Fabris, Mercedes A García, Mary-Carmen Amigo, Graciela Espada, Luis J Catoggio, Emilia Inoue Sato, Roger A Levy, Eduardo M Acevedo Vásquez, Rosa Chacón-Díaz, Claudio M Galarza-Maldonado, Antonio J Iglesias Gamarra, José Fernando Molina, Oscar Neira, Clóvis A Silva, Andrea Vargas Peña, José A Gómez-Puerta, Marina Scolnik, Guillermo J Pons-Estel, Michelle R Ugolini-Lopes, Verónica Savio, Cristina Drenkard, Alejandro J Alvarellos, Manuel F Ugarte-Gil, Alejandra Babini, André Cavalcanti, Fernanda Athayde Cardoso Linhares, Maria Jezabel Haye Salinas, Yurilis J Fuentes-Silva, Ana Carolina Montandon de Oliveira E Silva, Ruth M Eraso Garnica, Sebastián Herrera Uribe, Diana Gómez-Martín, Ricardo Robaina Sevrini, Rosana M Quintana, Sergio Gordon, Hilda Fragoso-Loyo, Violeta Rosario, Verónica Saurit, Simone App Referencia : Ann Rheum Dis. 2018 Nov;77(11):1549-1557. DOI (Digital Object Identifier) : 10.1136/annrheumdis-2018-213512 PMID : 30045853 En línea : https://ard.bmj.com/content/77/11/1549 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR) [documento electrónico] / Ruth María Eraso Garnica, Autor asociado al HPTU . - 2018.
Obra : Annals of the Rheumatic Diseases
Idioma : Inglés (eng)
Palabras clave : Lupus nephritis systemic lupus erythematosus treatment Resumen : Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therapeutic guidelines are developed. The objective of the study is to develop clinical practice guidelines for Latin American patients with lupus. Two independent teams (rheumatologists with experience in lupus management and methodologists) had an initial meeting in Panama City, Panama, in April 2016. They selected a list of questions for the clinical problems most commonly seen in Latin American patients with SLE. These were addressed with the best available evidence and summarised in a standardised format following the Grading of Recommendations Assessment, Development and Evaluation approach. All preliminary findings were discussed in a second face-to-face meeting in Washington, DC, in November 2016. As a result, nine organ/system sections are presented with the main findings; an 'overarching' treatment approach was added. Special emphasis was made on regional implementation issues. Best pharmacologic options were examined for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, haematological manifestations and the antiphospholipid syndrome. The roles of main therapeutic options (ie, glucocorticoids, antimalarials, immunosuppressant agents, therapeutic plasma exchange, belimumab, rituximab, abatacept, low-dose aspirin and anticoagulants) were summarised in each section. In all cases, benefits and harms, certainty of the evidence, values and preferences, feasibility, acceptability and equity issues were considered to produce a recommendation with special focus on ethnic and socioeconomic aspects. Guidelines for Latin American patients with lupus have been developed and could be used in similar settings. Mención de responsabilidad : Bernardo A Pons-Estel, Eloisa Bonfa, Enrique R Soriano, Mario H Cardiel, Ariel Izcovich, Federico Popoff, Juan M Criniti, Gloria Vásquez, Loreto Massardo, Margarita Duarte, Leonor A Barile-Fabris, Mercedes A García, Mary-Carmen Amigo, Graciela Espada, Luis J Catoggio, Emilia Inoue Sato, Roger A Levy, Eduardo M Acevedo Vásquez, Rosa Chacón-Díaz, Claudio M Galarza-Maldonado, Antonio J Iglesias Gamarra, José Fernando Molina, Oscar Neira, Clóvis A Silva, Andrea Vargas Peña, José A Gómez-Puerta, Marina Scolnik, Guillermo J Pons-Estel, Michelle R Ugolini-Lopes, Verónica Savio, Cristina Drenkard, Alejandro J Alvarellos, Manuel F Ugarte-Gil, Alejandra Babini, André Cavalcanti, Fernanda Athayde Cardoso Linhares, Maria Jezabel Haye Salinas, Yurilis J Fuentes-Silva, Ana Carolina Montandon de Oliveira E Silva, Ruth M Eraso Garnica, Sebastián Herrera Uribe, Diana Gómez-Martín, Ricardo Robaina Sevrini, Rosana M Quintana, Sergio Gordon, Hilda Fragoso-Loyo, Violeta Rosario, Verónica Saurit, Simone App Referencia : Ann Rheum Dis. 2018 Nov;77(11):1549-1557. DOI (Digital Object Identifier) : 10.1136/annrheumdis-2018-213512 PMID : 30045853 En línea : https://ard.bmj.com/content/77/11/1549 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares (1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000792 AC-2018-079 Archivo digital Producción Científica Artículos científicos Disponible Aggressive silent corticotroph adenoma progressing to pituitary carcinoma : the role of temozolomide therapy / Luis Vicente Syro Moreno
Título : Aggressive silent corticotroph adenoma progressing to pituitary carcinoma : the role of temozolomide therapy Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Autor asociado al HPTU Fecha de publicación : 2011 Títulos uniformes : Hormones Idioma : Inglés (eng) Palabras clave : Carcinoma MGMT pituitary adenoma temozolomide treatment Resumen : Temozolomide (TMZ) has recently been recommended as a novel approach in the management of aggressive pituitary tumors. Herein, we present the case of a 43-year-old man with a 20-year history of silent subtype 2 pituitary corticotroph adenoma. Nine surgical resections and radiotherapy had failed to provide a cure. Morphological evaluation of the tumor revealed a mildly pleomorphic adenoma, the cells of which showed low-level cell proliferative activity with Ki67, increased topoisomerase II alpha index and conclusive O-6-methylguanine-DNA methyltransferase (MGMT) as well as vascular endothelial growth factor (VEGF) immunoreactivity. Given its aggressive behavior and failure of conventional therapy, TMZ was administered. The treatment was continued even after MGMT immunopositivity was identified, but failed to decrease MGMT immunoexpression and exerted no morphologic effect. Examination of the lesion after TMZ therapy showed neither morphologic nor immunohistochemical alterations. In our case, TMZ administration, despite changing the TMZ dosing regimen to prompt a drug response, was incapable of depleting MGMT stores. Mención de responsabilidad : Olga Moshkin, Luis V Syro, Bernd W Scheithauer, Leon D Ortiz, Camilo E Fadul, Humberto Uribe, Ricardo Gonzalez, Michael Cusimano, Eva Horvath, Fabio Rotondo, Kalman Kovacs Referencia : Hormones (Athens). 2011 Apr-Jun;10(2):162-7. DOI (Digital Object Identifier) : 10.14310/horm.2002.1307 PMID : 21724542 En línea : https://link.springer.com/article/10.14310/horm.2002.1307 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Aggressive silent corticotroph adenoma progressing to pituitary carcinoma : the role of temozolomide therapy [documento electrónico] / Luis Vicente Syro Moreno, Autor asociado al HPTU . - 2011.
Obra : Hormones
Idioma : Inglés (eng)
Palabras clave : Carcinoma MGMT pituitary adenoma temozolomide treatment Resumen : Temozolomide (TMZ) has recently been recommended as a novel approach in the management of aggressive pituitary tumors. Herein, we present the case of a 43-year-old man with a 20-year history of silent subtype 2 pituitary corticotroph adenoma. Nine surgical resections and radiotherapy had failed to provide a cure. Morphological evaluation of the tumor revealed a mildly pleomorphic adenoma, the cells of which showed low-level cell proliferative activity with Ki67, increased topoisomerase II alpha index and conclusive O-6-methylguanine-DNA methyltransferase (MGMT) as well as vascular endothelial growth factor (VEGF) immunoreactivity. Given its aggressive behavior and failure of conventional therapy, TMZ was administered. The treatment was continued even after MGMT immunopositivity was identified, but failed to decrease MGMT immunoexpression and exerted no morphologic effect. Examination of the lesion after TMZ therapy showed neither morphologic nor immunohistochemical alterations. In our case, TMZ administration, despite changing the TMZ dosing regimen to prompt a drug response, was incapable of depleting MGMT stores. Mención de responsabilidad : Olga Moshkin, Luis V Syro, Bernd W Scheithauer, Leon D Ortiz, Camilo E Fadul, Humberto Uribe, Ricardo Gonzalez, Michael Cusimano, Eva Horvath, Fabio Rotondo, Kalman Kovacs Referencia : Hormones (Athens). 2011 Apr-Jun;10(2):162-7. DOI (Digital Object Identifier) : 10.14310/horm.2002.1307 PMID : 21724542 En línea : https://link.springer.com/article/10.14310/horm.2002.1307 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares (1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000118 AC-2011-003 Archivo digital Producción Científica Artículos científicos Disponible PermalinkPermalinkPermalinkActivity of two different triazoles in a murine model of paracoccidioidomycosis / Susana Restrepo ; Ángela María Tabares Velásquez ; Ángela Restrepo Moreno
Permalink